Ascendis Health will delist from the JSE in early December after 93% of shareholders backed the move, signalling strong support for its turnaround strategy, reported BusinessDay (19 Nov 2025). Once near bankruptcy, the company is now debt-free and valued at about R600m, up from less than R370m earlier this year. CEO Carl Neethling says operating privately will “enhance agility and support acquisition-led growth”, while CFO Lihle Mbele notes it will allow faster execution of strategy. Ascendis recently shifted from a pharmaceutical group to an investment holding company, cutting costs and boosting performance, driven largely by its growing medical devices portfolio.